Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Liver Neoplasms 1Liver Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 3atezolizumab 2Radiotherapy 2Bevacizumab 2tremelimumab 1temsirolimus 1lonafarnib 1liposomal doxorubicin 1infigratinib 1gadolinium ethoxybenzyl DTPA 1fludarabine 1durvalumab 1cabozantinib 1bavituximab 1aldesleukin 1Thoracoscopy 1Thoracic Surgery, Video-Assisted 1Resveratrol 1Radiosurgery 1Radionuclide Generators 1Radiofrequency Ablation 1Polymerase Chain Reaction 1Oxaliplatin 1Nivolumab 1NSC 366140 1Mass Spectrometry 1Immunotherapy 1Immunohistochemistry 1Genetic Testing 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Neoplasms × bavituximab × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡